Single-injection depot progesterone before surgery and survival in women with operable breast cancer: A randomized controlled trial

Journal of Clinical Oncology

Volumn 29, Issue 21, 2011, Pages 2845-2851

  Badwe, Rajendra ^a   Hawaldar, Rohini ^a   Parmar, Vani ^a   Nadkarni, Mandar ^a   Shet, Tanuja ^a   Desai, Sangeeta ^a   Gupta, Sudeep ^a   Jalali, Rakesh ^a   Vanmali, Vaibhav ^a   Dikshit, Rajesh ^a   Mittra, Indraneel ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HYDROXYPROGESTERONE; METHOTREXATE; TAMOXIFEN;

ADULT; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INJECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DELAYED-ACTION PREPARATIONS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXYPROGESTERONES; INDIA; INJECTIONS, INTRAMUSCULAR; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY; MENSTRUAL CYCLE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960720034     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.0738     Document Type: Conference Paper

References (35)

1. Hrushesky WJ, Bluming AZ, Gruber SA, et al: Menstrual influence on surgical cure of breast cancer. Lancet 338:949-952, 1989 (Pubitemid 19255748)
2. Ratajczak HV, Sothern RB, Hrushesky WJ: Estrous influence on surgical cure of a mouse breast cancer. J Exp Med 168:73-83, 1988
3. Badwe RA, Gregory WM, Chaudary MA, et al: Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 337:1261-1264, 1991
4. Badwe RA, Wang DY, Gregory WM, et al: Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer 30A:445-448, 1994 (Pubitemid 24171947)
5. Badwe RA, Mittra I, Havaldar R: Timing of surgery with regard to the menstrual cycle in women with primary breast cancer. Surg Clin North Am 79:1047-1059, 1999 (Pubitemid 29483218)
6. Thorpe H, Brown SR, Sainsbury JR, et al: Timing of breast cancer surgery in relation to menstrual cycle phase: No effect on 3-year prognosis - The ITS Study. Br J Cancer 98:39-44, 2008
7. Grant C, Ingle J, Suman V, et al: Menstrual cycle and surgical treatment of breast cancer: Findings from the NCCTG N9431 study. J Clin Oncol 27:3620-3626, 2009
8. Levine M, Myles J, Shephard N, et al: Optimal timing of breast cancer surgery within the menstrual cycle: Results from a prospective trial. Proc Am Soc Clin Oncol 15:99, 1996 (abstr 61)
9. Kroman N: Timing of breast cancer surgery in relation to the menstrual cycle: The rise and fall of a hypothesis. Acta Oncol 47:576-579, 2008
10. Hortobagyi GN: The influence of menstrual cycle phase on surgical treatment of primary breast cancer: Have we made any progress over the past 13 years? J Natl Cancer Inst 94:641-643, 2002
11. Onsrud M, Paus E, Haug E, et al: Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma: Pharmacokinetics and effects on adrenal function. Acta Obstet Gynecol Scand 64:519-523, 1985 (Pubitemid 15241030)
12. Pocock SJ: Group sequential methods in the design and analysis of clinical trials. Biometrika 64: 191-199, 1977
13. Badwe RA, Vaidya JS: Haematogenous dissemination of prostate epithelial cells during surgery. Lancet 347:325-326, 1996
14. Badwe RA: Re: Lung cancer mortality in the Mayo Lung Project: Impact of extended follow-up. J Natl Cancer Inst 93:321-323, 2001
15. Fisher B, Gunduz N, Coyle J, et al: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 49: 1996-2001, 1989
16. Veronesi U, Luini A, Mariani L, et al: Effect of menstrual phase on surgical treatment of breast cancer. Lancet 343:1545-1547, 1994 (Pubitemid 24180054)
17. Jain RK, Tong RT, Munn LL: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model. Cancer Res 67:2729-2735, 2007 (Pubitemid 46548961)
18. Kinmonth JB, Taylor GN, Harper AK: Lymphangiography: Technique for its clinical use in lower limb. BMJ 1:940-942, 1955
19. Graham JD, Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev 18:502-519, 1997
20. Poutanen M, Moncharmont B, Vihko R: 17-Beta hydroxy dehydrogenase gene expression in human breast cancer cells: Regulation of expression by progestin. Cancer Res 52:290-294, 1992
21. Rochfort H, Augereau P, Briozzo P: Structure, function, regulation and clinical significance of the 52K pro-cathepsin-D secretion by breast cancer cells. Biochimie 70:943-949, 1988
22. Saksela O, Rifkin DB: Cell associated plasminogen activation: Regulation and function. Annu Rev Cell Biol 4:93-126, 1988 (Pubitemid 19139253)
23. Oesterreich S, Deng W, Jiang S, et al: Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res 63:5203-5208, 2003 (Pubitemid 37139828)
24. Moyer DL, Sahwi SE, Maccaulay LK, et al: Cells of uterine fluid, in Beller FK, Schumacher GFB (eds), The biology of the fluids of the female genital tract. Amsterdam, the Netherlands, Elsevier North Holland, 1979, pp 59-71
25. Galán M, Viñolas N, Colomer D, et al: Detection of occult breast cancer cells by amplification of CK19 mRNA by reverse transcriptase-polymerase chain reaction: Role of surgical manipulation. Anticancer Res 22:2877-2884, 2002 (Pubitemid 36069328)
26. Lippman ME, Dickson RB, Bates S, et al: 8th San Antonio Breast Cancer Symposium-Plenary lecture: Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 7: 59-70, 1986 (Pubitemid 16096171)
27. Altucci L, Addeo R, Cicatiello L, et al: 17 Beta-estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12:2315-2324, 1996 (Pubitemid 26192711)
28. Hanna N, Schneider M: Enhancement of tumour metastasis and suppression of NK cell by beta-estradiol treatment. J Immunol 130:974-980, 1982
29. Witkiewicz AK, McConnell T, Potoczek M, et al: Increased natural killer cells and decreased regulatory T cells are seen in complex endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Hum Pathol 41:26-32, 2010
30. Mohr PE, Wang DY, Gregory WM, et al: Serum progesterone and prognosis in operable breast cancer. Br J Cancer 73:1552-1555, 1996 (Pubitemid 26235382)
31. Lin VCL, Woon CT, Aw SE, et al: Distinct molecular pathways mediate progesterone-induced growth inhibition and focal adhesion. Endocrinology 144:5650-5657, 2003 (Pubitemid 37476094)
32. Wiebe JP: Progesterone metabolites in breast cancer. Endocr Relat Cancer 13:717-738, 2006
33. Papa V, Hartmann KK, Rosenthal SM, et al: Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells role of IGF-II. Mol Endocrinol 5:709-717, 1991 (Pubitemid 21923723)
34. Creighton CJ, Casa A, Lazard Z, et al: Insulinlike growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26:4078-4085, 2008
35. Sankaranarayanan R, Swaminathan R, Brenner H, et al: Cancer survival in Africa, Asia, and Central America: A population-based study. Lancet Oncol 11:165-173, 2010